MedChem Australia is pleased to announce that applications for Round 3 of our project intake are now open. We invite Australian researchers leading innovative small molecule drug discovery programs to apply for subsidised access to our specialised medicinal chemistry and DMPK capabilities. 

This round offers an opportunity for Australian research teams to accelerate the development of their discoveries with support from an experienced, multidisciplinary project team. 

What MedChem Australia offers 

• A dedicated medicinal chemistry team  
• Support for DMPK research activities 
• Experts with a track record in translational drug discovery & development join your project team 

“We’ve seen excellent progress from the projects supported in earlier rounds.” says Professor Brendon Monahan, “Building on that success, Round 3 offers another opportunity for Australian researchers to receive tailored support and subsidised access to our expert team to advance their therapeutic innovations.” 

Eligibility 

• Any Australian drug discovery program with validated small molecule chemical matter  

Important Dates 

• Application Period: Now open 
• Deadline: 5:00 PM (AEST), Friday, 6 March 2026 

How to Apply 

Find all details about the application process, eligibility criteria, and project requirements in the ‘Working with Us’ section of our website.
Discussions regarding potential applications are welcome at any time. 

Schedule a confidential call to discuss your project here. 

About MedChem Australia 

MedChem Australia is a national drug discovery initiative that partners with Australian researchers to transform early-stage small molecule projects into commercially valuable, clinically relevant drug candidates. Through a competitive application process, selected projects receive expert medicinal chemistry and DMPK support at 80% subsidised cost. A collaboration between Monash University, the University of Sydney, and WEHI, MedChem Australia operates across the hit-to-lead and lead optimisation stages of drug discovery. Projects are advanced by experienced teams working within world-class facilities, with DMPK profiling provided by the Centre for Drug Candidate Optimisation (CDCO) at Monash. By delivering industry-grade capabilities and strategic collaboration, MedChem Australia accelerates the translation of Australian biomedical research into new therapeutics.